A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
ARTIVION, INC.
AORT
$1.2B
Mkt Cap
$25.28
+1.12%
ARTIVION, INC. (AORT) has a current P/E ratio of 120.4, compared to its historical median P/E of 60.6. The stock is currently considered Expensive based on its historical valuation range.
ARTIVION, INC. (AORT) has a 5-year average return on invested capital (ROIC) of 2.8%. This is below average and may indicate limited pricing power.
ARTIVION, INC. (AORT) has a market capitalization of $1.2B. It is classified as a small-cap stock.
ARTIVION, INC. (AORT) does not currently pay a regular dividend.
Based on historical P/E analysis, ARTIVION, INC. (AORT) appears expensive. The current P/E of 120.4 is 99% above its historical median of 60.6. The estimated fair value CAGR (P/E method) is -44.7%.
ARTIVION, INC. (AORT) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
ARTIVION, INC. (AORT) reported annual revenue of $441 million in its most recent fiscal year, based on SEC EDGAR filings.
Artivion, Inc. (“Artivion,” the “Company,” “we,” or “us”), is a leader in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. We have four major product families: aortic stent grafts, On-X® mechanical heart valves and related surgical products (“On-X” products), surgical sealants, and implantable cardiac and vascular human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Aortic arch stent grafts include our E-vita® Open NEO, E-vita Open Plus, Arcevo™ LSA Hybrid Stent Graft System (“Arcevo LSA”), the Ascyrus Medical Dissection Stent (“AMDS”) hybrid prosthesis, the NEXUS ONETM (“NEXUS ONE”), NEXUS DUOTM (“NEXUS DUO”), and NEXUS TRETM (“NEXUS TRE”) aortic arch stent graft systems (the “NEXUS family of products”), and E-vita Thoracic 3G products.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 441M | 441M | 389M | 354M | 314M | 299M |
| Net Income | 9.8M | 9.8M | -13M | -31M | -19M | -15M |
| EPS | $0.21 | $0.21 | $-0.32 | $-0.75 | $-0.48 | $-0.38 |
| Free Cash Flow | 839K | 839K | 11M | 9.1M | -16M | -16M |
| ROIC | 3.5% | 3.8% | 7.0% | 1.0% | 1.1% | 1.4% |
| Gross Margin | 64.4% | 64.4% | 64.0% | 64.7% | 64.5% | 66.1% |
| Debt/Equity | 0.57 | 0.57 | 1.30 | 1.27 | 1.24 | 1.19 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 34M | 34M | 39M | 5.7M | 6.2M | 8.1M |
| Operating Margin | 7.6% | 7.6% | 10.0% | 1.6% | 2.0% | 2.7% |
| ROE | 2.2% | 2.7% | -4.8% | -10.8% | -6.5% | -4.7% |
| Shares Outstanding | 46M | 46M | 42M | 41M | 40M | 39M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 145M | 146M | 180M | 190M | 263M | 276M | 253M | 299M | 314M | 354M | 389M | 441M | 441M |
| Gross Margin | 63.1% | 62.2% | 65.9% | 67.8% | 65.8% | 66.3% | 66.3% | 66.1% | 64.5% | 64.7% | 64.0% | 64.4% | 64.4% |
| R&D | 8.7M | 10M | 13M | 19M | 23M | 23M | 24M | 36M | 39M | 29M | 28M | 31M | 31M |
| SG&A | 74M | 75M | 92M | 101M | 141M | 143M | 141M | 170M | 157M | 209M | 181M | 226M | 226M |
| EBIT | 8.8M | 5.4M | 22M | 8.0M | 9.3M | 17M | 2.4M | 8.1M | 6.2M | 5.7M | 39M | 34M | 34M |
| Op. Margin | 6.1% | 3.7% | 12.1% | 4.2% | 3.5% | 6.2% | 1.0% | 2.7% | 2.0% | 1.6% | 10.0% | 7.6% | 7.6% |
| Net Income | 7.2M | 3.9M | 11M | 3.6M | -2.8M | 1.7M | -17M | -15M | -19M | -31M | -13M | 9.8M | 9.8M |
| Net Margin | 5.0% | 2.7% | 5.9% | 1.9% | -1.1% | 0.6% | -6.5% | -4.9% | -6.1% | -8.6% | -3.4% | 2.2% | 2.2% |
| Non-Recurring | 140K | 858K | 8.4M | 1.2M | 212K | 0 | 0 | 21M | 0 | 14M | 0 | 7.0M | 7.0M |
| Returns on Capital | |||||||||||||
| ROIC | 6.6% | 3.1% | 7.7% | 2.3% | 2.1% | 3.6% | 0.5% | 1.4% | 1.1% | 1.0% | 7.0% | 3.8% | 3.5% |
| ROE | 4.9% | 2.6% | 5.8% | 1.5% | -1.0% | 0.6% | -5.4% | -4.7% | -6.5% | -10.8% | -4.8% | 2.7% | 2.2% |
| ROA | 4.1% | 2.2% | 4.3% | 0.8% | -0.5% | 0.3% | -2.4% | -1.9% | -2.5% | -3.9% | -1.7% | 1.2% | 1.1% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 8.1M | 11M | 20M | 11M | 9.9M | 16M | 12M | -2.6M | -5.2M | 19M | 22M | 40M | 40M |
| Free Cash Flow | 3.8M | 8.0M | 14M | 4.2M | 4.1M | 7.8M | 5.0M | -16M | -16M | 9.1M | 11M | 839K | 839K |
| Owner Earnings | -1.3M | 490K | 5.0M | -5.9M | -15M | -11M | -15M | -37M | -40M | -19M | -16M | -7.0M | -7.0M |
| CapEx | 4.3M | 3.5M | 6.2M | 6.6M | 5.8M | 8.1M | 7.3M | 13M | 11M | 9.8M | 11M | 39M | 39M |
| Maint. CapEx | 6.0M | 5.9M | 8.4M | 9.7M | 18M | 18M | 21M | 24M | 22M | 23M | 24M | 22M | 22M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17M | 17M |
| D&A | 6.0M | 5.9M | 8.4M | 9.7M | 18M | 18M | 21M | 24M | 22M | 23M | 24M | 22M | 22M |
| CapEx/OCF | 53.1% | 30.5% | 31.4% | 61.4% | 58.6% | 51.0% | 59.2% | N/A | N/A | 51.8% | 50.3% | 97.9% | 97.9% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 3.3M | 3.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | 1.2% | 1.2% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 5.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 1.7% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 3.4M | 5.1M | 6.3M | 6.9M | 6.3M | 8.8M | 6.9M | 11M | 12M | 14M | 14M | 24M | 24M |
| Debt Repayment | 0 | 0 | 2.3M | 67M | 624K | 0 | 30M | 2.8M | 2.8M | 2.8M | 212M | 210K | 210K |
| Balance Sheet | |||||||||||||
| Net Debt | N/A | N/A | 14M | 178M | 175M | 205M | 250M | 302M | 313M | 298M | 306M | 192M | 192M |
| Cash & Equiv. | 33M | 38M | 57M | 40M | 41M | 34M | 61M | 55M | 39M | 59M | 53M | 65M | 65M |
| Long-Term Debt | N/A | N/A | 67M | 218M | 216M | 215M | 290M | 307M | 306M | 306M | 314M | 215M | 215M |
| Debt/Equity | 0.18 | 0.17 | 0.34 | 0.79 | 0.79 | 0.84 | 0.95 | 1.19 | 1.24 | 1.27 | 1.30 | 0.57 | 0.57 |
| Interest Coverage | 50.5 | 86.4 | 7.3 | 1.6 | 0.6 | 1.1 | 0.1 | 0.5 | 0.3 | 0.2 | 1.1 | 1.3 | 1.3 |
| Equity | 149M | 155M | 209M | 277M | 275M | 286M | 329M | 301M | 284M | 282M | 276M | 448M | 448M |
| Total Assets | 176M | 181M | 316M | 590M | 571M | 606M | 789M | 793M | 763M | 792M | 789M | 885M | 885M |
| Total Liabilities | 27M | 26M | 107M | 313M | 296M | 320M | 461M | 492M | 478M | 511M | 513M | 437M | 437M |
| Intangibles | 12M | 1.4M | 1.0M | 130M | 118M | 115M | 186M | 167M | 151M | 143M | 128M | 124M | 124M |
| Retained Earnings | 23M | 23M | 34M | 38M | 35M | 37M | 20M | 2.0M | -17M | -48M | -61M | -51M | -51M |
| Working Capital | 85M | 90M | 117M | 136M | 145M | 142M | 174M | 203M | 198M | 223M | 223M | 257M | 257M |
| Current Assets | 106M | 110M | 147M | 179M | 179M | 187M | 235M | 248M | 247M | 281M | 290M | 358M | 358M |
| Current Liabilities | 21M | 20M | 30M | 43M | 35M | 45M | 60M | 45M | 50M | 58M | 67M | 102M | 102M |
| Per Share Data | |||||||||||||
| EPS | 0.25 | 0.14 | 0.32 | 0.11 | -0.08 | 0.05 | -0.44 | -0.38 | -0.48 | -0.75 | -0.32 | 0.21 | 0.21 |
| Owner EPS | -0.05 | 0.02 | 0.15 | -0.18 | -0.41 | -0.33 | -0.41 | -0.96 | -1.00 | -0.46 | -0.39 | -0.15 | -0.15 |
| Book Value | 5.19 | 5.55 | 6.33 | 8.37 | 7.82 | 8.36 | 8.73 | 7.75 | 7.15 | 6.91 | 6.63 | 9.65 | 9.65 |
| Cash Flow/Share | 0.28 | 0.41 | 0.60 | 0.33 | 0.28 | 0.46 | 0.33 | -0.07 | -0.13 | 0.46 | 0.53 | 0.86 | 0.69 |
| Dividends/Share | 0.12 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 28.6M | 28.0M | 33.0M | 33.1M | 35.2M | 34.2M | 37.7M | 38.8M | 39.8M | 40.8M | 41.7M | 46.5M | 46.5M |
| Valuation | |||||||||||||
| P/E Ratio | 46.5 | 79.2 | 60.6 | 175.9 | N/A | 534.8 | N/A | N/A | N/A | N/A | N/A | 220.5 | 120.4 |
| P/FCF | 87.4 | 39.0 | 47.4 | 153.6 | 240.9 | 117.8 | 177.4 | N/A | N/A | 81.8 | 109.4 | N/A | N/A |
| EV/EBIT | N/A | N/A | 28.2 | 99.3 | 121.4 | 62.7 | 438.1 | 121.6 | 111.8 | 162.9 | 36.5 | 66.4 | 40.5 |
| Price/Book | 2.2 | 2.0 | 3.1 | 2.4 | 3.6 | 3.2 | 2.7 | 2.6 | 1.6 | 2.6 | 4.4 | 4.8 | 2.6 |
| Price/Sales | 1.9 | 2.1 | 2.6 | 3.4 | 3.6 | 3.5 | 3.2 | 3.2 | 2.3 | 1.7 | 2.5 | 3.6 | 2.7 |
| FCF Yield | 1.1% | 2.5% | 2.1% | 0.6% | 0.4% | 0.8% | 0.6% | -2.0% | -3.4% | 1.2% | 0.9% | 0.0% | 0.1% |
| Market Cap | 333M | 317M | 653M | 652M | 996M | 920M | 900M | 787M | 462M | 746M | 1.2B | 2.2B | 1.2B |
| Avg. Price | 9.72 | 10.57 | 13.78 | 18.95 | 26.65 | 27.76 | 21.55 | 24.43 | 17.77 | 14.77 | 23.69 | 34.24 | 25.28 |
| Year-End Price | 11.62 | 11.09 | 19.40 | 19.35 | 28.06 | 26.74 | 23.74 | 20.15 | 11.56 | 18.22 | 29.00 | 46.31 | 25.28 |
ARTIVION, INC. passes 1 of 9 quality checks, indicating weak fundamentals.
ARTIVION, INC. trades at 120.4x trailing earnings, compared to its 15-year median P/E of 60.6x, suggesting it is currently Expensive relative to its historical range. The company's 5-year average ROIC is 2.8% with a gross margin of 64.8%. At current prices, the estimated annualized return to fair value is -1.7%.
ARTIVION, INC. (AORT) has a net profit margin of 2.2%. This is a modest margin.
ARTIVION, INC. (AORT) generated $839 thousand in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
ARTIVION, INC. (AORT) has a debt-to-equity ratio of 0.57. This indicates moderate leverage.
ARTIVION, INC. (AORT) reported earnings per share (EPS) of $0.21 in its most recent fiscal year.
ARTIVION, INC. (AORT) has a return on equity (ROE) of 2.7%. This indicates moderate shareholder returns.
ARTIVION, INC. (AORT) has a 5-year average gross margin of 64.8%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for ARTIVION, INC. (AORT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ARTIVION, INC. (AORT) has a book value per share of $9.65, based on its most recent annual SEC filing.